CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

June 16, 2022 · Phase 2 readout

XFOR Phase 2 readout: a negative outcome, -5.3%

On June 16, 2022, X4P-001 — X4 Pharmaceuticals, Inc (WHIM Syndrome) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -5.3% in the window around the event.

The move

$33.90
1d before
$32.10
Event day
$32.40
1d after
$33.90
5d after

Pre-catalyst setup

+2.6%
30-day run-up
7428%
30-day volatility
0.5×
volume spike